NCT05066360

Serum Antimullerian Hormone Levels Among Epileptic Patients

Investigation of Serum Antimullerian Hormone Levels in Adolescent Epilepsy Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Near East University, Turkey · Academic / Other
• Sex: Female
• Age: 12 Years – 18 Years
• Healthy volunteers: Accepted

Summary

The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.

Conditions

• Epilepsy
• Reproductive Issues

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	serum antimullerian hormone	serum antimullerian hormone will be analyzed for all participants

Timeline

• Start date: 2021-07-02
• Primary completion: 2022-02-20
• Completion: 2023-06-20
• First posted: 2021-10-04
• Last updated: 2024-01-29

Locations

1 site across 1 country: Cyprus